Log inSign up
user avatar
Praxis Medicines
@PraxisMedicines
Praxis is translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance.
Cambridge, Massachusetts
praxismedicines.com
Joined April 2019
303
Following
663
Followers
  • Pinned
    user avatar
    Praxis Medicines
    @PraxisMedicines
    Jul 24, 2023
    At Praxis, our passion for developing treatments for children with #SCN2A and #SCN8A DEEs runs deep. Watch the video below to meet a few of the Praxis team members and learn more about our ongoing clinical trials in genetic epilepsies: emboldstudy.com.
    00:00
    6.3K
  • user avatar
    Praxis Medicines
    @PraxisMedicines
    Dec 13, 2024
    We had a great time at the @AmEpilepsySoc Meeting discussing the latest advancements in #epilepsy and our leading portfolio of precision epilepsy programs. Thank you to all who stopped by our booth, posters, & scientific exhibit. #ICYMI: bit.ly/4eAY1fS #AES2024
    00:00
    10M
  • user avatar
    Praxis Medicines
    @PraxisMedicines
    Feb 24, 2021
    At Praxis, we honor International #SCN2A Awareness Day and remain committed to providing therapies for patients as efficiently as possible. It’s inspiring to hear from parents, some of whom are our own colleagues, on the impact this #raredisease has on their children & families.
  • user avatar
    Praxis Medicines
    @PraxisMedicines
    Feb 9, 2022
    On #SCN8AAwarenessDay, we stand in solidarity with all those affected by SCN8A-related epilepsies, not just today but always. We want to thank and acknowledge the tireless work that advocates and advocacy groups do to support the #rareepilepsy community. #DareForMore
  • user avatar
    Praxis Medicines
    @PraxisMedicines
    Sep 26, 2024
    We are proud to be presenting at the @movedisorder #MDSCongress taking place Sept 27 - Oct 1! Mark your calendars for our presentations taking place Saturday and Sunday and stop by booth #1008 to learnmore about our journey to develop a new #EssentialTremor therapy.
    190K
  • user avatar
    Praxis Medicines
    @PraxisMedicines
    Aug 24, 2022
    At Praxis, we’re leveraging our curiosity and collaboration to #DareforMore and change the way #CNS drugs are developed. Learn more about what drives Praxis from CEO, Marcio Souza.
    00:00
  • user avatar
    Praxis Medicines
    @PraxisMedicines
    Aug 12, 2022
    Replying to @cureSYNGAP1 and @ciitizen
    As a team built of #rare parents, we’re proud to sponsor this initiative. We're grateful to your organization & the #SYNGAP1 community who are proactively gathering and sharing invaluable insights and using tools like @Ciitizen/@Invitae to help us move innovation forward quickly.
  • user avatar
    Praxis Medicines
    @PraxisMedicines
    Jan 7, 2021
    We are pleased to announce the FDA has granted both rare pediatric disease and orphan drug designations for #PRAX222 in SCN2A #epilepsy & rare pediatric disease designation for #PRAX562 in SCN2A & SCN8A epilepsies. Learn more here: bit.ly/3bf3b31 #RareDisease
  • user avatar
    Praxis Medicines
    @PraxisMedicines
    Apr 30, 2021
    We are pleased to announce the FDA has granted orphan drug designation for #PRAX562 in SCN2A development and epileptic encephalopathy (SCN2A-DEE). Learn more here: bit.ly/3e6byza #RareDisease
  • user avatar
    Praxis Medicines
    @PraxisMedicines
    Apr 27, 2022
    Today is our #EpilepsyDay. Tune in to learn more about our epilepsy programs, hear from our management team and #epilepsy KOLs as they discuss the role of genetics in finding new treatments for rare and prevalent epilepsies, and more: bit.ly/3JQJXi9
    00:00
  • user avatar
    Praxis Medicines
    @PraxisMedicines
    Sep 6, 2022
    The needs of patients with #CNS disorders are devastatingly urgent. Learn more about our work w/@invitae to accelerate & optimize the development of new therapies for #epilepsy by breaking #data silos & gathering real-world data: bit.ly/3AiRbsa #SCN2A #SCN8A #SYNGAP1
    00:00
  • user avatar
    Praxis Medicines
    @PraxisMedicines
    Feb 16, 2021
    Today we announce our innovative collaboration with @ciitizen to improve patient-guided drug development across multiple disease populations. Initial focus of this partnership will be to inform development of #PRAX222 and #PRAX562 in SCN2A-DEE. Learn more:
    investors.praxismedicines.com
    Praxis Precision Medicines Partners With Ciitizen to Improve Patient-Guided Drug Development -...
    Innovative collaboration to be implemented across multiple indications starting with SCN2A-DEE CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a...
  • user avatar
    Praxis Medicines
    @PraxisMedicines
    Jun 21, 2023
    We’re supporting #Syngap1AwarenessDay and raising awareness for those living with #SYNGAP1 epilepsy. Learn more about SYNGAP1, access resources, and support tools by connecting with advocacy organizations like @cureSYNGAP1, @Syngap1Fnd, @SyngapNetwork and more.
    434
  • user avatar
    Praxis Medicines
    @PraxisMedicines
    Feb 28, 2022
    To show our support for #RareDiseaseDay this year, Praxons joined our patient advocacy partners to create a one-of-a-kind community collage filled with messages of hope, inspiration, and action. Check out the below video to see what we built together! #ShowYourStripes
    00:00